{"altmetric_id":17341132,"counts":{"readers":{"mendeley":3,"citeulike":0,"connotea":0},"total":{"posts_count":26},"news":{"unique_users_count":2,"unique_users":["oncology_nurse_advisor","the_asco_post"],"posts_count":3},"twitter":{"unique_users_count":17,"unique_users":["JournalCancer","lopezgovlaw","DrFadloKhuri","SuzieSiegel","talbotrlibrary","NasserDq","biomedicalsc","Winette_vdGraaf","dr_ssaMichela","Infosarcomes","PinnieMearl","entrepweekly","alitimumab","NormanGoldfarb","AntoineCOR2ED","Sharon_Goddard","12Dublin"],"posts_count":23}},"selected_quotes":["Doxorubicin-refractory soft-tissue #sarcoma: Regorafenib improves quality-adjusted survival compared to placebo","REGOSARC: Regorafenib vs placebo in doxorubicin-refractory soft-tissue sarcoma:outcome,QoL Tox analyses (Q-TWISTs) h\u2026","Regorafenib vs placebo in doxorubicin-refractory soft-tissue sarcoma: analysis of quality-adjusted time w\/o symptoms htt\u2026","#regorafenib significantly improved quality-adjusted survival in doxorubicin-pretreated soft-tissue sarcoma","#Regorafenib better than nothing for some #sarcoma patients who have already tried doxorubicin. #leiomyosarcoma"],"citation":{"abstract":"In a placebo-controlled, randomized phase 2 trial (ClinicalTrials.gov identifier NCT01900743), regorafenib improved progression-free survival (PFS) for patients with doxorubicin-pretreated advanced nonadipocytic sarcoma. A quality-adjusted time without symptoms of progression or toxicity (Q-TWiST) post hoc exploratory analysis was applied to provide an integrated measure of its clinical benefit.\nIn the base-case analysis, each patient's overall survival (OS) was partitioned into 3 mutually exclusive health states: the time with a grade 3 or 4 adverse event (TOX), the time without symptoms of disease or grade 3 or 4 toxicity from treatment, and the time after tumor progression or relapse. The time spent in each state was weighted with a health-state utility associated with that state and was summed to calculate the Q-TWiST. The stability of the base-case analysis was explored with several sensitivity analyses.\nIn nonadipocytic sarcoma, the PFS was (4.0 months [2.6-5.5 months] with regorafenib vs 1.0 month [0.9-1.8 months] with a placebo; hazard ratio, 0.36 [0.25-0.53]; P < .0001); the OS was 13.4 months (8.6-17.3 months) with regorafenib and 9.0 months (6.8-12.5 months) with a placebo (hazard ratio, 0.67 [0.44-1.02]). With the classic definition of TOX (including all grade 3 and 4 clinical adverse events), the Q-TWiSTs were 8.0 months (7.0-9.0 months) with regorafenib and 5.7 months (4.9-6.4 months) with a placebo (P\u2002<\u2002.001).\nFor patients with doxorubicin-pretreated soft-tissue sarcoma, regorafenib significantly improved quality-adjusted survival in comparison with a placebo. Cancer 2017. \u00a9 2017 American Cancer Society.","altmetric_jid":"4f6fa4e93cf058f610002494","authors":["Berry, Vincent","Basson, Laurent","Bogart, Emilie","Mir, Olivier","Blay, Jean\u2010Yves","Italiano, Antoine","Bertucci, Fran\u00e7ois","Chevreau, Christine","Clisant\u2010Delaine, St\u00e9phanie","Liegl\u2010Antzager, Bernadette","Tresch\u2010Bruneel, Emmanuelle","Wallet, Jennifer","Taieb, Sophie","Decoupigny, Emilie","Cesne, Axel","Brodowicz, Thomas","Penel, Nicolas","Vincent Berry","Laurent Basson","Emilie Bogart","Olivier Mir","Jean-Yves Blay","Antoine Italiano","Fran\u00e7ois Bertucci","Christine Chevreau","St\u00e9phanie Clisant-Delaine","Bernadette Liegl-Antzager","Emmanuelle Tresch-Bruneel","Jennifer Wallet","Sophie Taieb","Emilie Decoupigny","Axel Le Cesne","Thomas Brodowicz","Nicolas Penel"],"doi":"10.1002\/cncr.30661","first_seen_on":"2017-03-14T14:45:15+00:00","funders":["niehs"],"issns":["0008543X","1097-0142"],"journal":"Cancer (0008543X)","last_mentioned_on":1504013908,"links":["http:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cncr.30661\/full","http:\/\/dx.doi.org\/10.1002\/cncr.30661","https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/28295221"],"pdf_url":"http:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cncr.30661\/pdf","pmid":"28295221","pubdate":"2017-03-10T00:00:00+00:00","publisher_subjects":[{"name":"Oncology And Carcinogenesis","scheme":"era"}],"scopus_subjects":["Health Sciences","Medicine","Life Sciences","Biochemistry, Genetics and Molecular Biology"],"subjects":["neoplasms"],"title":"REGOSARC: Regorafenib versus placebo in doxorubicin-refractory soft-tissue sarcoma-A quality-adjusted time without symptoms of progression or toxicity analysis","type":"article","uri":"http:\/\/doi.wiley.com\/10.1002\/cncr.30661","mendeley_url":"http:\/\/www.mendeley.com\/research\/regosarc-regorafenib-versus-placebo-doxorubicinrefractory-softtissue-sarcomaa-qualityadjusted-time-w"},"altmetric_score":{"score":27.15,"score_history":{"1y":27.15,"6m":10.1,"3m":1.1,"1m":0,"1w":0,"6d":0,"5d":0,"4d":0,"3d":0,"2d":0,"1d":0,"at":27.15},"context_for_score":{"all":{"total_number_of_other_articles":8454572,"mean":7.1053083078883,"rank":337766,"this_scored_higher_than_pct":96,"this_scored_higher_than":8116619,"rank_type":"exact","sample_size":8454572,"percentile":96},"similar_age_3m":{"total_number_of_other_articles":245182,"mean":13.657811013088,"rank":19582,"this_scored_higher_than_pct":92,"this_scored_higher_than":225585,"rank_type":"exact","sample_size":245182,"percentile":92},"this_journal":{"total_number_of_other_articles":5910,"mean":13.892687764427,"rank":448,"this_scored_higher_than_pct":92,"this_scored_higher_than":5460,"rank_type":"exact","sample_size":5910,"percentile":92},"similar_age_this_journal_3m":{"total_number_of_other_articles":167,"mean":50.306939759036,"rank":42,"this_scored_higher_than_pct":74,"this_scored_higher_than":124,"rank_type":"exact","sample_size":167,"percentile":74}}},"demographics":{"poster_types":{"member_of_the_public":8,"researcher":1,"practitioner":2,"science_communicator":6},"users":{"twitter":{"cohorts":{"Science communicators (journalists, bloggers, editors)":6,"Members of the public":8,"Scientists":1,"Practitioners (doctors, other healthcare professionals)":2}},"mendeley":{"by_status":{"Unspecified":1,"Researcher":1,"Other":1},"by_discipline":{"Medicine and Dentistry":1,"Unspecified":2}}},"geo":{"twitter":{"US":7,"LB":2,"FR":2},"mendeley":{"IT":1}}},"posts":{"twitter":[{"url":"http:\/\/twitter.com\/JournalCancer\/statuses\/841661445339152391","license":"gnip","citation_ids":[17341132],"posted_on":"2017-03-14T14:45:00+00:00","author":{"name":"ACS Journal Cancer","url":"http:\/\/www.canceronlinejournal.com\/","image":"https:\/\/pbs.twimg.com\/profile_images\/708058565030907904\/JjiXwvyC_normal.jpg","description":"An interdisciplinary journal of the American Cancer Society.\n&emsp;&emsp;&emsp;&emsp;\nEditor-in-Chief: Fadlo R. Khuri, MD (@DrFadloKhuri)","id_on_source":"JournalCancer","tweeter_id":"19077568","geo":{"lt":33.749,"ln":-84.38798,"country":"US"},"followers":20078},"tweet_id":"841661445339152391"},{"url":"http:\/\/twitter.com\/lopezgovlaw\/statuses\/841663716936548354","license":"gnip","rt":["JournalCancer"],"citation_ids":[17341132],"posted_on":"2017-03-14T14:54:02+00:00","author":{"name":"Jorge Luis Lopez Esq","url":"http:\/\/www.LopezGovLaw.com","image":"https:\/\/pbs.twimg.com\/profile_images\/612000460342448128\/Xgz6KteQ_normal.jpg","description":"Gov't Affairs Attorney | TV & Radio Analyst | Board: @AmericanCancer + @ACSCAN + @SFLRedCross + @BGCMia | Sponsor: @MiamiGives + @SurveySunday + @DailyPsalms365","id_on_source":"lopezgovlaw","tweeter_id":"92677101","geo":{"lt":25.77427,"ln":-80.19366,"country":"US"},"followers":6846},"tweet_id":"841663716936548354"},{"url":"http:\/\/twitter.com\/DrFadloKhuri\/statuses\/841682738293936129","license":"gnip","rt":["JournalCancer"],"citation_ids":[17341132],"posted_on":"2017-03-14T16:09:37+00:00","author":{"name":"Dr. Fadlo Khuri","url":"http:\/\/www.aub.edu.lb","image":"https:\/\/pbs.twimg.com\/profile_images\/578920575680167936\/ZwEfDtB9_normal.png","description":"President, American University of Beirut, Hematologist\/Oncologist; lung and head\/neck cancer expert. Editor-in-chief, @JournalCancer. Opinions=my own","id_on_source":"DrFadloKhuri","tweeter_id":"2230534242","geo":{"lt":33.88894,"ln":35.49442,"country":"LB"},"followers":3935},"tweet_id":"841682738293936129"},{"url":"http:\/\/twitter.com\/SuzieSiegel\/statuses\/841822837665062912","license":"gnip","rt":["JournalCancer"],"citation_ids":[17341132],"posted_on":"2017-03-15T01:26:19+00:00","author":{"name":"Suzie Siegel","image":"https:\/\/pbs.twimg.com\/profile_images\/910167963604578309\/0OVMnNuA_normal.jpg","description":"Newspaper reporter & editor before  metastatic #leiomyosarcoma.  #Ostomate. Master's in women's studies. Former board member of #Sarcoma Alliance.","id_on_source":"SuzieSiegel","tweeter_id":"850054435","geo":{"lt":27.94752,"ln":-82.45843,"country":"US"},"followers":708},"tweet_id":"841822837665062912"},{"url":"http:\/\/twitter.com\/talbotrlibrary\/statuses\/842014171743023105","license":"gnip","citation_ids":[17341132],"posted_on":"2017-03-15T14:06:37+00:00","author":{"name":"Talbot Library","url":"http:\/\/talbotresearchlibrary.wordpress.com\/","image":"https:\/\/pbs.twimg.com\/profile_images\/3055135669\/a57f377e0df6404c7272ecab3b6c3ab0_normal.png","description":"Talbot Library is the information hub for Fox Chase Cancer Center. We can help w\/EndNote, lit searches, systematic reviews, etc. We also have a sense of humor.","id_on_source":"talbotrlibrary","tweeter_id":"28645539","geo":{"lt":39.95234,"ln":-75.16379,"country":"US"},"followers":152},"tweet_id":"842014171743023105"},{"url":"http:\/\/twitter.com\/JournalCancer\/statuses\/842447125074042881","license":"gnip","citation_ids":[17341132],"posted_on":"2017-03-16T18:47:01+00:00","author":{"name":"ACS Journal Cancer","url":"http:\/\/www.canceronlinejournal.com\/","image":"https:\/\/pbs.twimg.com\/profile_images\/708058565030907904\/JjiXwvyC_normal.jpg","description":"An interdisciplinary journal of the American Cancer Society.\n&emsp;&emsp;&emsp;&emsp;\nEditor-in-Chief: Fadlo R. Khuri, MD (@DrFadloKhuri)","id_on_source":"JournalCancer","tweeter_id":"19077568","geo":{"lt":33.749,"ln":-84.38798,"country":"US"},"followers":20078},"tweet_id":"842447125074042881"},{"url":"http:\/\/twitter.com\/lopezgovlaw\/statuses\/842448699607392256","license":"gnip","rt":["JournalCancer"],"citation_ids":[17341132],"posted_on":"2017-03-16T18:53:16+00:00","author":{"name":"Jorge Luis Lopez Esq","url":"http:\/\/www.LopezGovLaw.com","image":"https:\/\/pbs.twimg.com\/profile_images\/612000460342448128\/Xgz6KteQ_normal.jpg","description":"Gov't Affairs Attorney | TV & Radio Analyst | Board: @AmericanCancer + @ACSCAN + @SFLRedCross + @BGCMia | Sponsor: @MiamiGives + @SurveySunday + @DailyPsalms365","id_on_source":"lopezgovlaw","tweeter_id":"92677101","geo":{"lt":25.77427,"ln":-80.19366,"country":"US"},"followers":6846},"tweet_id":"842448699607392256"},{"url":"http:\/\/twitter.com\/DrFadloKhuri\/statuses\/842448794063106051","license":"gnip","rt":["JournalCancer"],"citation_ids":[17341132],"posted_on":"2017-03-16T18:53:39+00:00","author":{"name":"Dr. Fadlo Khuri","url":"http:\/\/www.aub.edu.lb","image":"https:\/\/pbs.twimg.com\/profile_images\/578920575680167936\/ZwEfDtB9_normal.png","description":"President, American University of Beirut, Hematologist\/Oncologist; lung and head\/neck cancer expert. Editor-in-chief, @JournalCancer. Opinions=my own","id_on_source":"DrFadloKhuri","tweeter_id":"2230534242","geo":{"lt":33.88894,"ln":35.49442,"country":"LB"},"followers":3935},"tweet_id":"842448794063106051"},{"url":"http:\/\/twitter.com\/NasserDq\/statuses\/842450147229503494","license":"gnip","rt":["JournalCancer"],"citation_ids":[17341132],"posted_on":"2017-03-16T18:59:01+00:00","author":{"name":"Nasser DaqDouqa","image":"https:\/\/pbs.twimg.com\/profile_images\/809102167718105090\/jm-GdCw1_normal.jpg","id_on_source":"NasserDq","tweeter_id":"2835799395","geo":{"lt":null,"ln":null},"followers":200},"tweet_id":"842450147229503494"},{"url":"http:\/\/twitter.com\/SuzieSiegel\/statuses\/842534930383028224","license":"gnip","rt":["JournalCancer"],"citation_ids":[17341132],"posted_on":"2017-03-17T00:35:55+00:00","author":{"name":"Suzie Siegel","image":"https:\/\/pbs.twimg.com\/profile_images\/910167963604578309\/0OVMnNuA_normal.jpg","description":"Newspaper reporter & editor before  metastatic #leiomyosarcoma.  #Ostomate. Master's in women's studies. Former board member of #Sarcoma Alliance.","id_on_source":"SuzieSiegel","tweeter_id":"850054435","geo":{"lt":27.94752,"ln":-82.45843,"country":"US"},"followers":708},"tweet_id":"842534930383028224"},{"url":"http:\/\/twitter.com\/biomedicalsc\/statuses\/842760420779687936","license":"gnip","rt":["JournalCancer"],"citation_ids":[17341132],"posted_on":"2017-03-17T15:31:56+00:00","author":{"name":"J Biomedical Sci","image":"https:\/\/pbs.twimg.com\/profile_images\/812238543892295680\/UF4pxtlY_normal.jpg","description":"I am a Journal Coordinator at present handling Journal of Biomedical Sciences. Biomedical Sciences acts as a bridge between the medicine and engineering.","id_on_source":"biomedicalsc","tweeter_id":"797708356488044544","geo":{"lt":39.00039,"ln":-75.49992,"country":"US"},"followers":31},"tweet_id":"842760420779687936"},{"url":"http:\/\/twitter.com\/Winette_vdGraaf\/statuses\/842834181063397376","license":"gnip","citation_ids":[17341132],"posted_on":"2017-03-17T20:25:02+00:00","author":{"name":"WinetteVanDerGraaf","url":"http:\/\/www.icr.ac.uk","image":"https:\/\/pbs.twimg.com\/profile_images\/726457161488977920\/KCQQpKeW_normal.jpg","description":"Sarcoma, Rare & AYA Cancer. Prof of Personalised Oncology @ICR_London @royalmarsden & Radboud umc NL","id_on_source":"Winette_vdGraaf","tweeter_id":"2878551394","geo":{"lt":null,"ln":null},"followers":1106},"tweet_id":"842834181063397376"},{"url":"http:\/\/twitter.com\/SuzieSiegel\/statuses\/842871491733733377","license":"gnip","citation_ids":[17341132],"posted_on":"2017-03-17T22:53:18+00:00","author":{"name":"Suzie Siegel","image":"https:\/\/pbs.twimg.com\/profile_images\/910167963604578309\/0OVMnNuA_normal.jpg","description":"Newspaper reporter & editor before  metastatic #leiomyosarcoma.  #Ostomate. Master's in women's studies. Former board member of #Sarcoma Alliance.","id_on_source":"SuzieSiegel","tweeter_id":"850054435","geo":{"lt":27.94752,"ln":-82.45843,"country":"US"},"followers":708},"tweet_id":"842871491733733377"},{"url":"http:\/\/twitter.com\/dr_ssaMichela\/statuses\/843023277840916481","license":"gnip","rt":["Winette_vdGraaf"],"citation_ids":[17341132],"posted_on":"2017-03-18T08:56:26+00:00","author":{"name":"Michela Libertini","image":"https:\/\/pbs.twimg.com\/profile_images\/696428011437092864\/15hGphUw_normal.jpg","description":"Medical Oncologist focusing on soft tissue and bone sarcomas","id_on_source":"dr_ssaMichela","tweeter_id":"2276246414","geo":{"lt":null,"ln":null},"followers":80},"tweet_id":"843023277840916481"},{"url":"http:\/\/twitter.com\/Infosarcomes\/statuses\/843070073208233985","license":"gnip","rt":["Winette_vdGraaf"],"citation_ids":[17341132],"posted_on":"2017-03-18T12:02:23+00:00","author":{"name":"INFO SARCOMES","url":"http:\/\/infosarcomes.org","image":"https:\/\/pbs.twimg.com\/profile_images\/464634036556558336\/m56Va3sX_normal.jpeg","description":"Information sur les sarcomes, soutien \u00e0 la recherche afin de favoriser l'harmonisation et l'am\u00e9lioration de la prise en charge de ces cancers rares en France.","id_on_source":"Infosarcomes","tweeter_id":"70114054","geo":{"lt":46,"ln":2,"country":"FR"},"followers":216},"tweet_id":"843070073208233985"},{"url":"http:\/\/twitter.com\/PinnieMearl\/statuses\/843093576372420608","license":"gnip","rt":["Winette_vdGraaf"],"citation_ids":[17341132],"posted_on":"2017-03-18T13:35:47+00:00","author":{"name":"Marije Weidema","url":"https:\/\/pinniemearl.wordpress.com\/","image":"https:\/\/pbs.twimg.com\/profile_images\/869548962755350535\/VlZr5eb5_normal.jpg","description":"Kersverse dokter, werkt & onderzoekt bij oncologie @Radboudumc, hartstochtelijk fan #personcentredcare, wil #dokterwordenenmensblijven.","id_on_source":"PinnieMearl","tweeter_id":"380965500","geo":{"lt":null,"ln":null},"followers":419},"tweet_id":"843093576372420608"},{"url":"http:\/\/twitter.com\/entrepweekly\/statuses\/843833676144218112","license":"gnip","rt":["JournalCancer"],"citation_ids":[17341132],"posted_on":"2017-03-20T14:36:40+00:00","author":{"name":"ci entrepreneur","url":"http:\/\/entrepreneurslb.network","image":"https:\/\/pbs.twimg.com\/profile_images\/801050225452470272\/Bmv3YQCb_normal.jpg","description":"entrepreneur magazine","id_on_source":"entrepweekly","tweeter_id":"801048787242323968","geo":{"lt":33.83333,"ln":35.83333,"country":"LB"},"followers":84},"tweet_id":"843833676144218112"},{"url":"http:\/\/twitter.com\/alitimumab\/statuses\/845574458198904832","license":"gnip","citation_ids":[17341132],"posted_on":"2017-03-25T09:53:55+00:00","author":{"name":"Abdelali Majdi","image":"https:\/\/pbs.twimg.com\/profile_images\/689580159402414081\/p8G0AVT2_normal.jpg","id_on_source":"alitimumab","tweeter_id":"86147599","geo":{"lt":46,"ln":2,"country":"FR"},"followers":383},"tweet_id":"845574458198904832"},{"url":"http:\/\/twitter.com\/NormanGoldfarb\/statuses\/846079783314239488","license":"gnip","rt":["alitimumab"],"citation_ids":[17341132],"posted_on":"2017-03-26T19:21:54+00:00","author":{"name":"Norman Goldfarb","url":"http:\/\/magiworld.org","image":"https:\/\/pbs.twimg.com\/profile_images\/846803737209270272\/oHNuVxIo_normal.jpg","description":"Chairman, MAGI and Editor, Journal of Clinical Research Best Practices  https:\/\/www.linkedin.com\/in\/ngoldfarb Advancing the practice of clinical research","id_on_source":"NormanGoldfarb","tweeter_id":"703973186","geo":{"lt":37.77493,"ln":-122.41942,"country":"US"},"followers":1288},"tweet_id":"846079783314239488"},{"url":"http:\/\/twitter.com\/AntoineCOR2ED\/statuses\/846813250532626433","license":"gnip","rt":["alitimumab"],"citation_ids":[17341132],"posted_on":"2017-03-28T19:56:26+00:00","author":{"name":"Antoine Lacombe","url":"http:\/\/Www.cor2ed.com","image":"https:\/\/pbs.twimg.com\/profile_images\/735778806913339395\/VQYG2A4I_normal.jpg","description":"co-founder at COR2ED, innovative company for Medical Education.","id_on_source":"AntoineCOR2ED","tweeter_id":"719588640171696129","geo":{"lt":null,"ln":null},"followers":20},"tweet_id":"846813250532626433"},{"url":"http:\/\/twitter.com\/Sharon_Goddard\/statuses\/848004705485824000","license":"gnip","rt":["Winette_vdGraaf"],"citation_ids":[17341132],"posted_on":"2017-04-01T02:50:51+00:00","author":{"name":"ClearSkies","image":"https:\/\/pbs.twimg.com\/profile_images\/898619450659934209\/GWC4MFst_normal.jpg","description":"21 yrs. Pharmaceutical & Device Clinical Trial Management Consultant","id_on_source":"Sharon_Goddard","tweeter_id":"322737879","geo":{"lt":39.76,"ln":-98.5,"country":"US"},"followers":886},"tweet_id":"848004705485824000"},{"url":"http:\/\/twitter.com\/SuzieSiegel\/statuses\/902524759384186880","license":"gnip","citation_ids":[17341132],"posted_on":"2017-08-29T13:34:05+00:00","author":{"name":"Suzie Siegel","image":"https:\/\/pbs.twimg.com\/profile_images\/910167963604578309\/0OVMnNuA_normal.jpg","description":"Newspaper reporter & editor before  metastatic #leiomyosarcoma.  #Ostomate. Master's in women's studies. Former board member of #Sarcoma Alliance.","id_on_source":"SuzieSiegel","tweeter_id":"850054435","geo":{"lt":27.94752,"ln":-82.45843,"country":"US"},"followers":708},"tweet_id":"902524759384186880"},{"url":"http:\/\/twitter.com\/12Dublin\/statuses\/902525862876151808","license":"gnip","rt":["SuzieSiegel"],"citation_ids":[17341132],"posted_on":"2017-08-29T13:38:28+00:00","author":{"name":"Nikki Shepherd","image":"https:\/\/pbs.twimg.com\/profile_images\/809578422200635392\/eQrAeRdY_normal.jpg","id_on_source":"12Dublin","tweeter_id":"708114097","geo":{"lt":null,"ln":null},"followers":799},"tweet_id":"902525862876151808"}],"news":[{"title":"Regorafenib Improves Quality-adjusted Survival in Sarcoma","url":"http:\/\/www.oncologynurseadvisor.com\/regorafenib-provides-survival-benefit-in-some-sarcoma-instances\/article\/645018\/","license":"public","citation_ids":[4692192,17341132],"posted_on":"2017-03-17T19:00:00+00:00","summary":"March 17, 2017 There is growing evidence that regorafenib can improve QoL in patients with advanced soft tissue sarcomas.","author":{"name":"Oncology Nurse Advisor ","url":"http:\/\/www.oncologynurseadvisor.com\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/276\/normal\/Screen_Shot_2014-11-20_at_11.19.42.png?1416482413"}},{"title":"Regorafenib Improves Quality-adjusted Survival in Sarcoma","url":"http:\/\/ct.moreover.com\/?a=29934360381&p=1pl&v=1&x=UOAXlvkdVlX6zr8Gwst9DA","license":"public","citation_ids":[4692192,17341132],"posted_on":"2017-03-17T19:00:00+00:00","summary":"March 17, 2017 There is growing evidence that regorafenib can improve QoL in patients with advanced soft tissue sarcomas.","author":{"name":"Oncology Nurse Advisor ","url":"http:\/\/www.oncologynurseadvisor.com\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/276\/normal\/Screen_Shot_2014-11-20_at_11.19.42.png?1416482413"}},{"title":"Pazopanib of Benefit in Imatinib- and Sunitinib-Resistant GIST in French Phase II Trial","url":"http:\/\/ct.moreover.com\/?a=30658021428&p=1pl&v=1&x=mXbXXdir_yQQbd-HyugiCw","license":"public","citation_ids":[17341132,20107666],"posted_on":"2017-05-22T23:04:45+00:00","summary":"By Matthew Stenger Posted: 4\/20\/2016 9:44:02 AM Last Updated: 4\/20\/2016 9:44:02 AM Tweet this page Advertisement Pazopanib increased progression-free survival in imatinib- and sunitinib-resistant GIST.","author":{"name":"The ASCO Post","url":"http:\/\/www.ascopost.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/000\/496\/normal\/Screen_Shot_2016-02-03_at_09.24.05.png?1454491455"}}]}}